AIM ImmunoTech signs manufacturing pact with Sterling Pharma, cost seen at $1.5 million

Reuters2026/08/06 22:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AIM ImmunoTech entered a proposal agreement on July 31, 2026 with Sterling Pharma Solutions to manufacture additional PolyI and Poly C12U batches.
Work will be carried out at Sterling’s Dudley, UK site, including transfer of associated test methods to support Ampligen polymer precursor production.
Estimated cost is about $1.5 million, paid over 12 months.
Output is intended to support ongoing and future clinical trials, including a potential Phase 3 study in metastatic pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-036408), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AIM ImmunoTech signs manufacturing pact with Sterling Pharma, cost seen at $1.5 million

You may also like

Crypto prices